Loading...

VERV VERVE THERAPEUTICS INC Product Launches 8-K Filing

VRV

VRV

VERVE THERAPEUTICS INC

(VERV)

2025 8-K

Show Summary

Show Summary

Merger of Equals

Financial Statements

Clinical Trial Update

Financial Results

Financial Results

Financial Results Announcement

Board Expansion and New Dir...

Update on Advisory Vote on ...

Annual Meeting of Stockholders

Appointment of Chief Scient...

Financial Results Announcement

Clinical Trial Pause

Financial Results Announcement

Underwriting Agreement

Interim Data Presentation

Financial Results Announcement

FDA Clearance for Clinical ...

Financial Results Announcement

Annual Meeting Results

Research Collaboration Agre...

Financial Results Announcement

Financial Results Announcement

Bylaws Amendment

External Links:

On April 14, 2025, Verve Therapeutics reported positive initial safety and efficacy data from its Heart-2 Phase 1b clinical trial of VERVE-102, showing significant reductions in LDL cholesterol levels among participants, with a maximum reduction of 6

AI Assistant

VERVE THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.